Targeted Delivery of Aptamers and siRNAs for HIV Prevention and Therapies in Humanized Mice

Neff, C. Preston; Akkina, Ramesh

doi:10.1007/978-1-4939-1655-9_31

Cited by 1 publication

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yang et al [49] discovered recently that the S1 protein of RBD can serve as a more stable binding site than RBD to enhance the kinetic and interaction time between aptamer-based drug molecules and the receptor, leading to a stronger interaction potency [50]. The same team also demonstrated a good dose-dependent inhibitory effect and neutralization performance of the designed aptamer (nCoV-S1-Apt) on S1/ACE2 binding and viral infection.…”

Section: Aptamersmentioning

confidence: 98%

“…However, the study also reported the accumulation of the formulation in the liver and peripheral blood mononuclear cells [91]. Vivian [92] proposed the development of a novel biosensor via dendrimer-gold platforms and conjugated with an either an aptamer for the detection of HIV in biological samples [50]. These reports show the potential of aptamer-dendrimer combinations in the development of a wide range of theranostics for viruses and viral diseases, including SARS-CoV-2.…”

Section: Dendrimer Nanoformulations Drugs and Theranosticsmentioning

confidence: 99%

See 1 more Smart Citation

Aptamer-Mediated Antiviral Approaches for SARS-CoV-2

Tan¹,

Jeevanandam²,

Rodrigues³

et al. 2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

2020 and 2021 were disastrous years across the world, with the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus as a pandemic, which continues to be a top global health issue. There are still many countries and regions struggling to fight coronavirus disease 2019 (COVID-19), and, with the emergence of the various variants of the virus, we are still far from considering this global pandemic over. In addition to having good diagnostic tools and a variety of vaccines with high efficacy, it is of utmost importance to develop effective antiviral drugs or therapies to battle COVID-19. Aptamers known as the next-generation targeting elements can offer promising opportunities in developing antiviral drugs against SARS-CoV-2. This is owing to their high specificity and affinity, making them ideal for targeting ligands and neutralizers to impede both, viral entry and replication or even further enhance the anti-infection effects in the infected host cells. Also, aptamers are extremely attractive as they can be rapidly synthesized and scalable with a lower production cost. This work provides in-depth discussions on the potential of aptamers in therapeutic applications, their mode of action, and current progress on the use of aptamer-based therapies against SARS-CoV-2 and other viruses. The article also discusses the limitations associated with aptamer-based SARS-CoV-2-antiviral therapy with several proposed ideas to resolve them. Lastly, theranostic applications of aptamer nanoformulated dendrimers against viral infections are discussed.

show abstract

Section: Aptamersmentioning

confidence: 98%

Section: Dendrimer Nanoformulations Drugs and Theranosticsmentioning

confidence: 99%